This week, the FDA is due to decide on four therapeutic applications, including one for Huntington’s disease and two for ultra-rare diseases.
Teva Pharmaceutical Industries’ US affiliate Teva Pharmaceuticals has reported findings from the ARC-HD clinical trial of Austedo (deutetrabenazine) tablets to treat patients with chorea linked to Huntington’s disease (HD).
The multicentre, three-year, single-arm, open-label, two-cohort, extension trial assessed the safety and tolerability of long-term use of Austedo in these patients.